BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease

Ferdows Atiq; Karin Fijnvandraat; Karin P. M. van Galen; B. A. P. Laros-van Gorkom; Karina Meijer; J. de Meris; Michiel Coppens; E. P. Mauser-Bunschoten; M. H. Cnossen; J. G. van der Bom; Jeroen Eikenboom; F. W. G. Leebeek; K. Fijnvandraat; M. Coppens; A. Kors; S. Zweegman; G. J. Goverde; M. H. Jonkers; N. Dors; M. R. Nijziel; L. Nieuwenhuizen; K. Meijer; R. Y. J. Tamminga; P. W. van der Linden; P. F. Ypma; H. C. J. Eikenboom; F. J. W. Smiers; B. Granzen; K. Hamulyak; P. Brons; F. Atiq; K. P. M. van Galen; WiN Study Group

doi:10.1002/ajh.25499

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease

Ferdows Atiq, Karin Fijnvandraat, Karin P. M. van Galen, B. A. P. Laros-van Gorkom, Karina Meijer, J. de Meris, Michiel Coppens, E. P. Mauser-Bunschoten, M. H. Cnossen, J. G. van der Bom, Jeroen Eikenboom, F. W. G. Leebeek^*, K. Fijnvandraat, M. Coppens, A. Kors, S. Zweegman, G. J. Goverde, M. H. Jonkers, N. Dors, M. R. NijzielL. Nieuwenhuizen, K. Meijer, R. Y. J. Tamminga, P. W. van der Linden, P. F. Ypma, H. C. J. Eikenboom, F. J. W. Smiers, B. Granzen, K. Hamulyak, P. Brons, F. Atiq, K. P. M. van Galen, WiN Study Group

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	E201-E205
Number of pages	6
Journal	American Journal of Hematology
Volume	94
Issue number	8
DOIs	https://doi.org/10.1002/ajh.25499
Publication status	Published - Aug 2019

Access to Document

10.1002/ajh.25499Licence: CC BY-NC-ND

Cite this

Atiq, F., Fijnvandraat, K., van Galen, K. P. M., Laros-van Gorkom, B. A. P., Meijer, K., de Meris, J., Coppens, M., Mauser-Bunschoten, E. P., Cnossen, M. H., van der Bom, J. G., Eikenboom, J., Leebeek, F. W. G., Fijnvandraat, K., Coppens, M., Kors, A., Zweegman, S., Goverde, G. J., Jonkers, M. H., Dors, N., ... WiN Study Group (2019). BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. American Journal of Hematology, 94(8), E201-E205. https://doi.org/10.1002/ajh.25499

@article{aa85e6ba339049248bdfa5fdd61f8612,

title = "BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease",

author = "Ferdows Atiq and Karin Fijnvandraat and {van Galen}, {Karin P. M.} and {Laros-van Gorkom}, {B. A. P.} and Karina Meijer and {de Meris}, J. and Michiel Coppens and Mauser-Bunschoten, {E. P.} and Cnossen, {M. H.} and {van der Bom}, {J. G.} and Jeroen Eikenboom and Leebeek, {F. W. G.} and K. Fijnvandraat and M. Coppens and A. Kors and S. Zweegman and Goverde, {G. J.} and Jonkers, {M. H.} and N. Dors and Nijziel, {M. R.} and L. Nieuwenhuizen and K. Meijer and Tamminga, {R. Y. J.} and {van der Linden}, {P. W.} and Ypma, {P. F.} and Eikenboom, {H. C. J.} and Smiers, {F. J. W.} and B. Granzen and K. Hamulyak and P. Brons and F. Atiq and {van Galen}, {K. P. M.} and {WiN Study Group}",

note = "Funding Information: F. Atiq received the professor Heimburger Award 2018. F.W.G. Lee-beek received research support from CSL Behring and Shire/Takeda for performing the Willebrand in the Netherlands (WiN) study, and is consultant for uniQure, Novo Nordisk and Shire/Takeda, of which the fees go to the institution. J. Eikenboom received research support from CSL Behring and he has been a teacher on educational activities of Roche. K. P. M. van Galen received unrestricted research support from CSL Behring and Bayer. E.P. Mauser-Bunschoten received unrestricted research/ educational support from CSL Behring, Bayer, Baxter, Grifols, Novo Nordisk, Pfizer, Biotest, Roche and Sanquin. J.G. van der Bom has been a teacher on educational activities of Bayer. M.H. Cnossen has received unrestricted research/educational and travel funding from the following companies: Pfizer, Baxter, Bayer Schering Pharma, CSL Behring, Novo Nordisk and Novartis, and serves as a member on steering boards of Roche and Bayer of which fees go to the institution. K. Fijnvandraat is a member of the European Hemophilia Treatment and Standardization Board sponsored by Baxter, has received unrestricted research grants from CSL Behring and Bayer, and has given lectures at educational symposiums organized by Pfizer, Bayer and Baxter. K. Meijer received research support from Bayer, Sanquin and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, BMS and Aspen; consulting fees from Uniqure, of which all fees go to the institution. B. Laros-van Gorkom has received unrestricted educational grants from Baxter and CSL Behring. M. Coppens has received research support, lecturing and consulting fees from Bayer, CSL Behring, UniQure, Sanquin and Sanofi. All fees were received by his institution. None of the other authors has a conflict of interest to declare. Funding Information: This study was supported (in part) by research funding from the Dutch Hemophilia Foundation (Stichting Hemophilia) and CSL Behring (unrestricted grant).",

year = "2019",

month = aug,

doi = "10.1002/ajh.25499",

language = "English",

volume = "94",

pages = "E201--E205",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley",

number = "8",

}

Atiq, F, Fijnvandraat, K, van Galen, KPM, Laros-van Gorkom, BAP, Meijer, K, de Meris, J, Coppens, M, Mauser-Bunschoten, EP, Cnossen, MH, van der Bom, JG, Eikenboom, J, Leebeek, FWG, Fijnvandraat, K, Coppens, M, Kors, A, Zweegman, S, Goverde, GJ, Jonkers, MH, Dors, N, Nijziel, MR, Nieuwenhuizen, L, Meijer, K, Tamminga, RYJ, van der Linden, PW, Ypma, PF, Eikenboom, HCJ, Smiers, FJW, Granzen, B, Hamulyak, K, Brons, P, Atiq, F, van Galen, KPM & WiN Study Group 2019, 'BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease', American Journal of Hematology, vol. 94, no. 8, pp. E201-E205. https://doi.org/10.1002/ajh.25499

TY - JOUR

T1 - BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease

AU - Atiq, Ferdows

AU - Fijnvandraat, Karin

AU - van Galen, Karin P. M.

AU - Laros-van Gorkom, B. A. P.

AU - Meijer, Karina

AU - de Meris, J.

AU - Coppens, Michiel

AU - Mauser-Bunschoten, E. P.

AU - Cnossen, M. H.

AU - van der Bom, J. G.

AU - Eikenboom, Jeroen

AU - Leebeek, F. W. G.

AU - Fijnvandraat, K.

AU - Coppens, M.

AU - Kors, A.

AU - Zweegman, S.

AU - Goverde, G. J.

AU - Jonkers, M. H.

AU - Dors, N.

AU - Nijziel, M. R.

AU - Nieuwenhuizen, L.

AU - Meijer, K.

AU - Tamminga, R. Y. J.

AU - van der Linden, P. W.

AU - Ypma, P. F.

AU - Eikenboom, H. C. J.

AU - Smiers, F. J. W.

AU - Granzen, B.

AU - Hamulyak, K.

AU - Brons, P.

AU - Atiq, F.

AU - van Galen, K. P. M.

AU - WiN Study Group

N1 - Funding Information: F. Atiq received the professor Heimburger Award 2018. F.W.G. Lee-beek received research support from CSL Behring and Shire/Takeda for performing the Willebrand in the Netherlands (WiN) study, and is consultant for uniQure, Novo Nordisk and Shire/Takeda, of which the fees go to the institution. J. Eikenboom received research support from CSL Behring and he has been a teacher on educational activities of Roche. K. P. M. van Galen received unrestricted research support from CSL Behring and Bayer. E.P. Mauser-Bunschoten received unrestricted research/ educational support from CSL Behring, Bayer, Baxter, Grifols, Novo Nordisk, Pfizer, Biotest, Roche and Sanquin. J.G. van der Bom has been a teacher on educational activities of Bayer. M.H. Cnossen has received unrestricted research/educational and travel funding from the following companies: Pfizer, Baxter, Bayer Schering Pharma, CSL Behring, Novo Nordisk and Novartis, and serves as a member on steering boards of Roche and Bayer of which fees go to the institution. K. Fijnvandraat is a member of the European Hemophilia Treatment and Standardization Board sponsored by Baxter, has received unrestricted research grants from CSL Behring and Bayer, and has given lectures at educational symposiums organized by Pfizer, Bayer and Baxter. K. Meijer received research support from Bayer, Sanquin and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, BMS and Aspen; consulting fees from Uniqure, of which all fees go to the institution. B. Laros-van Gorkom has received unrestricted educational grants from Baxter and CSL Behring. M. Coppens has received research support, lecturing and consulting fees from Bayer, CSL Behring, UniQure, Sanquin and Sanofi. All fees were received by his institution. None of the other authors has a conflict of interest to declare. Funding Information: This study was supported (in part) by research funding from the Dutch Hemophilia Foundation (Stichting Hemophilia) and CSL Behring (unrestricted grant).

PY - 2019/8

Y1 - 2019/8

U2 - 10.1002/ajh.25499

DO - 10.1002/ajh.25499

M3 - Comment/Letter to the editor

C2 - 31037771

SN - 0361-8609

VL - 94

SP - E201-E205

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 8

ER -